AlignRT Used by All 15 of the Top 15 “Best Hospitals for Cancer”

Vision RT’s AlignRT technology is once again being used by all 15 of the top 15 “Best Hospitals for Cancer” in the United States, according to the latest analysis by U.S. News and World Report.

The new 2022-2023 rankings evaluated 914 hospitals and ranked the top 50 according to a set of health equity measurements including survival rates and patient experience. U.S. News and World Report’s annual listing is designed to assist patients and their doctors in making critical healthcare decisions. For the second year in a row, Vision RT’s Surface Guided Radiation Therapy (SGRT) technology is being used by all 15 of the top-ranked 15 centers, delivering exceptional treatment across many areas of care.

“With millions of people around the world diagnosed with cancer every year, we know that every treatment counts,” said Vision RT’s CEO, Dr. Norman Smith. “Which is why establishing SGRT as the standard of care in advanced radiation therapy is our goal each and every day. We are extremely proud to see Vision RT’s systems adopted by the most prestigious hospitals in the USA. We will continue our work to ensure that every patient receives accurate, safe, and comfortable cancer treatment.”

Vision RT’s AlignRT technology uses proprietary 3D stereo camera units to monitor a patient’s skin surface in real-time and compare it to the ideal position with sub-millimetric accuracy. This ensures that radiation is delivered only when a patient is correctly positioned, enhancing safety and comfort. AlignRT is non-invasive and completely non-contact, an increasingly important advantage for cancer patients, who often have weakened immune systems.

___

Vision RT defines the standard of care in Surface Guided Radiation Therapy (SGRT). With +100 granted patents and +40 pending, Vision RT continues to innovate in the radiation oncology space and is committed to making SGRT the standard of care for all patients, worldwide. There are more than 2,000 systems installed worldwide.